Valuation: OliX Pharmaceuticals, Inc

Market Cap 2,657B 1.98B 1.77B 1.65B 1.5B 2.82B 191B 2.84B 19.9B 7.74B 97.42B 7.44B 7.28B 314B P/E 2026 *
-75.5x
P/E 2027 * -77.6x
Enterprise Value 2,657B 1.98B 1.77B 1.65B 1.5B 2.82B 191B 2.84B 19.9B 7.74B 97.42B 7.44B 7.28B 314B EV / Sales 2026 *
332x
EV / Sales 2027 * 242x
Free-Float
84.71%
Yield 2026 *
-
Yield 2027 * -
08-14 OliX Pharmaceuticals, Inc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-30 OliX Pharmaceuticals, Inc Reports Preclinical Data Demonstrating Greater Visceral Fat Reduction with Olx501a Versus Global Comparator in Obese Non-Human Primates CI
07-08 OliX Pharmaceuticals, Inc announced that it has received KRW 10.526832833 billion in funding from Business Opportunities for L'Oréal Development CI
06-29 OliX Pharmaceuticals, Inc announced that it expects to receive KRW 10.526832833 billion in funding from Business Opportunities for L'Oréal Development CI
06-04 OliX Pharmaceuticals, Inc announced that it has received KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP CI
06-01 OliX Pharmaceuticals, Inc announced that it expects to receive KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP CI
05-15 OliX Pharmaceuticals, Inc Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-01 Ollix Receives Patent Registration Decision from the United States Patent and Trademark Office CI
03-16 OliX Pharmaceuticals, Inc Reports Earnings Results for the Full Year Ended December 31, 2025 CI
02-08 Vect-Horus Reports CNS-Focused Research Collaboration with OliX Pharmaceuticals CI
12-02 Olix Pharmaceuticals receives milestone payment from L'Oréal RE
11-14 OliX Pharmaceuticals, Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
28/08/25 OliX Pharmaceuticals, Inc announced that it has received KRW 115.002040047 billion in funding from a group of investors CI
1 day-0.09%
1 week+13.73%
Current month+13.95%
1 month+21.79%
3 months-21.77%
6 months-28.78%
Current year-16.81%
1 week 99,700
Extreme 99700
119,200
1 month 92,600
Extreme 92600
119,200
Current year 86,600
Extreme 86600
217,000
1 year 84,000
Extreme 84000
217,000
3 years 8,280
Extreme 8280
217,000
5 years 8,280
Extreme 8280
217,000
10 years 8,280
Extreme 8280
217,000
Manager TitleAgeSince
Chief Executive Officer 54 01/02/2010
Director of Finance/CFO 40 -
Corporate Officer/Principal 51 28/03/2022
Director TitleAgeSince
Director/Board Member 61 19/03/2019
Director/Board Member 55 19/03/2019
Chairman 54 01/02/2010
Date Insider Type Main position Quantity % Market Cap. Importance
28/02/25 Exercice

Director

30,000 0.1625%
28/02/25 Exercice

Chief Technology Officer

8,000 0.0433%
Change 5-day change 1-year change 3-year change Capi.($)
-0.09%+13.73%+27.37%+650.64% 1.97B
+4.16%+3.04%+49.37%+94.17% 74.16B
-0.37%-3.88%+19.75%+78.35% 57.39B
+1.63%+0.98%+3.83%+38.21% 47.64B
+0.50%+1.32%+344.62%+753.25% 44.29B
+3.05%-1.58%+28.78%+35.46% 42.5B
+1.00%+0.22%+5.17%+113.80% 40.71B
-0.54%+2.93%+9.31%+54.06% 30.97B
+1.56%+4.53%+31.34%+26.92% 28.53B
+0.76%-0.89%-7.44%-11.43% 24.34B
Average +1.17%+0.66%+51.21%+183.34% 39.25B
Weighted average by Cap. +1.54%-0.78%+57.91%+143.31%

Financials

2026 *2027 *
Net sales 8B 5.97M 5.32M 4.96M 4.52M 8.5M 575M 8.56M 59.9M 23.3M 293M 22.41M 21.92M 945M 11B 8.21M 7.32M 6.82M 6.22M 11.69M 790M 11.77M 82.37M 32.04M 403M 30.81M 30.14M 1.3B
Net income -31B -23.13M -20.62M -19.22M -17.52M -32.95M -2.23B -33.17M -232M -90.3M -1.14B -86.83M -84.94M -3.66B -30B -22.38M -19.95M -18.6M -16.95M -31.89M -2.16B -32.1M -225M -87.39M -1.1B -84.03M -82.2M -3.54B
Net Debt - -
Logo OliX Pharmaceuticals, Inc
OliX Pharmaceuticals, Inc. is a Korea-based company principally engaged in the research and development of new drugs for intractable diseases based on ribonucleic acid interference (RNAi) platform technologies. The Company’s product profile consists of OLX101, OLX102, OLX103, OLX104, OLX201, OLX301, OLX401 and others. These products are used for the treatment of hypertrophic scars and keloids, atopic dermatitis, androgenic alopecia, diabetic ulcer, age-related macular degeneration (AMD), idiopathic pulmonary fibrosis, neuropathic pain, liver fibrosis. In addition, these products are applied for skin brightening, anti-wrinkle and others. The Company operates its business within domestic market and to overseas markets.
Employees
81
Date Price Change Volume
02/10/26 ₩116,800.00 -0.09% 182,339
01/10/26 ₩116,900.00 +14.05% 440,833
30/09/26 ₩102,500.00 -0.29% 123,514
29/09/26 ₩102,800.00 -1.53% 154,619
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A226950 Stock